Global Oral Transmucosal Drugs Market - 2023 -2030
Oral Transmucosal Drugs Market Size
The global oral transmucosal drugs market reached USD 15,005.2 million in 2022 and is projected to witness lucrative growth by reaching up to USD 24,441.4 million by 2030. The market is expected to exhibit a CAGR of 6.4% during the forecast period (2023-2030).
Oraltransmucosal drug administration was an alternative route in end-of-life care and palliative care during the COVID-19 pandemic. Oral transmucosal drug delivery is the systemic distribution of drugs through the mucous membrane of the oral cavity. It is a preferred approach in palliative care compared to other transmucosal drug delivery since it is practical and easy to use. Oral transmucosal drug delivery is a different method for delivering dose formulations for oral or nasal administration.
The increase in incidence of autoimmune disorders, cancer cases, and respiratory issues, technological advancements, and the rise in research activities by the key players about novel oral transmucosal drugs drive the global oral transmucosal drugs market growth.
Oral Transmucosal Drugs Market Dynamics
Increase in the incidence of autoimmune disorders and, cancer to boost the market growth.
Due to the rise in autoimmune illnesses and cancer, the global market for oral transmucosal drugs is likely to grow during the forecast period. Oral cancer and autoimmune illnesses are all diseases that are affecting more and more people worldwide. This increases demand for oral transmucosal medications as they can prevent gastrointestinal degradation and have an immediate start of action.
For instance, according to the CDC's National Diabetes Statistics Report, there are expected to be 37.3 million cases of diabetes worldwide in 2022. About 11.3% of Americans, or 37.3 million people, have diabetes. The 28.5% of the population, or an estimated 28.7 million people, had diabetes, due to which, the demand for transmucosal medications also increases.
Regulatory challenges for the transmucosal drugwill hamperthe globaloral transmucosal drugs marketgrowth.
Regulatory challenges are one of the major factors that can impact the development and commercialization of transmucosal drugs. Some of the regulatory challenges faced by transmucosal drugs include: like all pharmaceutical products, transmucosal drugs must undergo rigorous safety and efficacy testing to gain regulatory approval.
Oral Transmucosal Drugs Market Segment Analysis
The global oral transmucosal drugs market is segmented based on product type, indication, route of administration, distributionchannel and region.
The tablets segment is expected to hold a dominant position in the market over the forecast period.
Tablets segment accounted for the highest market stake, accounting for approximately 47% of the oral transmucosal drugs market share in 2022, owing to the benefits provided by oral transmucosal tablets are including quick absorption, the convenience of administration, less interaction with other medications, and the factors mentioned above helps tablets segment is likely to hold a significant share of the market. For instance, according to a study published in the National Library of Medicine's Journal in August 2021, older adults who take multiple medications frequently experience a decrease in salivary output. The study also revealed that dental risks for older adults who have low resting pH and low stimulated salivary flow rates increase by 63%.
Oral Transmucosal Drugs Market Geographical Share
North America holds a dominant position in the global oral transmucosal drugs market.
North America is estimated to hold about 37% of the totaloral transmucosal drugs market share overthe forecast period.The active regional players and availability of drugs and opioid use disorders helpdrive the market growth in North America. For instance, as per the article published in Stat Pearls in 2022, in the U.S. and throughout the world, opioid use disorder and addiction are still at pandemic levels.
Opioid use disorder (OUD) has affected 3 million American residents and 16 million other people, worldwide. In the U.S., heroin dependence affects more than 500,000 people. The demand for the prescription of opioid drugs is unquenchable in the U.S.
Oral Transmucosal Drugs Market Companies
The major global players in the market include Pfizer Inc., ZIM Laboratories Limited, Aquestive Therapeutics, Inc, IntelGenx Corp, Indivior PLC, C.L.Pharm Co., Ltd, Seoul Pharmaceuticals, Shilpa Therapeutics, Sunovion Pharmaceuticals, Inc, and CURE Pharmaceutical, among others.
Russia Ukraine Conflict Analysis
The Russia-Ukraine conflict is estimated to have a minimal impact on the global oral transmucosal drugs market, owing to the low prevalence and absence of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global oral transmucosal drugs market over the forecast period.
Artificial Intelligence Impact Analysis
Artificial intelligence is expecetd to impact positively for the global oral transmucosal drugsmarket. Artificial neural networks (ANNs), information technology, and wireless communication all play a role in the development of smart medication delivery systems that have the potential to overcome the drawbacks of traditional therapeutic approaches. Devices for regulated drug distribution have more versatility because of the wireless connection.
Key Developments
Target Audience 2023
The global oral transmucosal drugs market reached USD 15,005.2 million in 2022 and is projected to witness lucrative growth by reaching up to USD 24,441.4 million by 2030. The market is expected to exhibit a CAGR of 6.4% during the forecast period (2023-2030).
Oraltransmucosal drug administration was an alternative route in end-of-life care and palliative care during the COVID-19 pandemic. Oral transmucosal drug delivery is the systemic distribution of drugs through the mucous membrane of the oral cavity. It is a preferred approach in palliative care compared to other transmucosal drug delivery since it is practical and easy to use. Oral transmucosal drug delivery is a different method for delivering dose formulations for oral or nasal administration.
The increase in incidence of autoimmune disorders, cancer cases, and respiratory issues, technological advancements, and the rise in research activities by the key players about novel oral transmucosal drugs drive the global oral transmucosal drugs market growth.
Oral Transmucosal Drugs Market Dynamics
Increase in the incidence of autoimmune disorders and, cancer to boost the market growth.
Due to the rise in autoimmune illnesses and cancer, the global market for oral transmucosal drugs is likely to grow during the forecast period. Oral cancer and autoimmune illnesses are all diseases that are affecting more and more people worldwide. This increases demand for oral transmucosal medications as they can prevent gastrointestinal degradation and have an immediate start of action.
For instance, according to the CDC's National Diabetes Statistics Report, there are expected to be 37.3 million cases of diabetes worldwide in 2022. About 11.3% of Americans, or 37.3 million people, have diabetes. The 28.5% of the population, or an estimated 28.7 million people, had diabetes, due to which, the demand for transmucosal medications also increases.
Regulatory challenges for the transmucosal drugwill hamperthe globaloral transmucosal drugs marketgrowth.
Regulatory challenges are one of the major factors that can impact the development and commercialization of transmucosal drugs. Some of the regulatory challenges faced by transmucosal drugs include: like all pharmaceutical products, transmucosal drugs must undergo rigorous safety and efficacy testing to gain regulatory approval.
Oral Transmucosal Drugs Market Segment Analysis
The global oral transmucosal drugs market is segmented based on product type, indication, route of administration, distributionchannel and region.
The tablets segment is expected to hold a dominant position in the market over the forecast period.
Tablets segment accounted for the highest market stake, accounting for approximately 47% of the oral transmucosal drugs market share in 2022, owing to the benefits provided by oral transmucosal tablets are including quick absorption, the convenience of administration, less interaction with other medications, and the factors mentioned above helps tablets segment is likely to hold a significant share of the market. For instance, according to a study published in the National Library of Medicine's Journal in August 2021, older adults who take multiple medications frequently experience a decrease in salivary output. The study also revealed that dental risks for older adults who have low resting pH and low stimulated salivary flow rates increase by 63%.
Oral Transmucosal Drugs Market Geographical Share
North America holds a dominant position in the global oral transmucosal drugs market.
North America is estimated to hold about 37% of the totaloral transmucosal drugs market share overthe forecast period.The active regional players and availability of drugs and opioid use disorders helpdrive the market growth in North America. For instance, as per the article published in Stat Pearls in 2022, in the U.S. and throughout the world, opioid use disorder and addiction are still at pandemic levels.
Opioid use disorder (OUD) has affected 3 million American residents and 16 million other people, worldwide. In the U.S., heroin dependence affects more than 500,000 people. The demand for the prescription of opioid drugs is unquenchable in the U.S.
Oral Transmucosal Drugs Market Companies
The major global players in the market include Pfizer Inc., ZIM Laboratories Limited, Aquestive Therapeutics, Inc, IntelGenx Corp, Indivior PLC, C.L.Pharm Co., Ltd, Seoul Pharmaceuticals, Shilpa Therapeutics, Sunovion Pharmaceuticals, Inc, and CURE Pharmaceutical, among others.
Russia Ukraine Conflict Analysis
The Russia-Ukraine conflict is estimated to have a minimal impact on the global oral transmucosal drugs market, owing to the low prevalence and absence of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global oral transmucosal drugs market over the forecast period.
Artificial Intelligence Impact Analysis
Artificial intelligence is expecetd to impact positively for the global oral transmucosal drugsmarket. Artificial neural networks (ANNs), information technology, and wireless communication all play a role in the development of smart medication delivery systems that have the potential to overcome the drawbacks of traditional therapeutic approaches. Devices for regulated drug distribution have more versatility because of the wireless connection.
Key Developments
- On May 21, 2022, ZIM Laboratories Limited announced that AEPMS, the Spanish Agency for Medicine and Healthcare Products, granted marketing authorization to its fully owned European subsidiary, SIA ZIM Laboratories Limited, for its novel product, 'Sildenafil 50 mg' ODS, in Spain.
- On December 22, 2022, Aquestive Therapeutics, Inc.'s End-of-Phase 2 (EOP2) meeting with the US Food and Drug Administration ('FDA') for AQST-109 was announced by the company
- On September 28, 2022, Aquestive Therapeutics, Inc., a pharmaceutical company, announced that it entered into a license agreement of supply for Libervant (diazepam) Buccal Film.
- To visualize the global oral transmucosal drugs market segmentation based on product type, Indication, end-user, and region, as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of oral transmucosal drugs market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as Excel consisting of key products of all the major players.
Target Audience 2023
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
1. METHODOLOGY AND SCOPE
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Snippet by Product Type
3.2. Snippet by Indication
3.3. Snippet by Route of Administration
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increase in incidence of autoimmune disorders, respiratory problems, and cancer to boost the market growth
4.1.1.2. The increase in medication and pharmacological therapy usage
4.1.2. Restraints
4.1.2.1. Regulatory challenges for transmucosal drug
4.1.3. Opportunity
4.1.3.1. Increasing number of research and developments activities
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
6. COVID-19 ANALYSIS
6.1. Analysis of COVID-19
6.1.1. Before COVID-19 Scenario
6.1.2. Present COVID-19 Scenario
6.1.3. Post COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. RUSSIA-UKRAINE CONFLICT ANALYSIS
8. GLOBAL RECESSION ANALYSIS
9. ARTIFICIAL INTELLIGENCE IMPACT ANALYSIS
10. BY PRODUCT TYPE
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.1.2. Market Attractiveness Index, By Product Type
10.2. Tablets
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Films
10.4. Liquids & Spray
10.5. Others
11. BY INDICATION
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
11.1.2. Market Attractiveness Index, By Indication
11.2. Opioid Dependence *
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Neurological Disorders
11.4. Erectile Dysfunction
11.5. Nausea and Vomiting
11.6. Others
12. BY ROUTE OF ADMINISTRATION
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.1.2. Market Attractiveness Index, By Route of Administration
12.2. Sublingual Mucosa *
12.2.1. Introduction
12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.3. Buccal Mucosa
12.4. Others
13. BY DISTRIBUTION CHANNEL
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13.1.2. Market Attractiveness Index, By Distribution Channel
13.2. Retail Pharmacies*
13.2.1. Introduction
13.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
13.3. Hospital Pharmacies
13.4. Online Pharmacies
14. BY REGION
14.1. Introduction
14.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
14.1.2. Market Attractiveness Index, By Region
14.2. North America
14.2.1. Introduction
14.2.2. Key Region-Specific Dynamics
14.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
14.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
14.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
14.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.2.7.1. The U.S.
14.2.7.2. Canada
14.2.7.3. Mexico
14.3. Europe
14.3.1. Introduction
14.3.2. Key Region-Specific Dynamics
14.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
14.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
14.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
14.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.3.7.1. Germany
14.3.7.2. The U.K.
14.3.7.3. France
14.3.7.4. Italy
14.3.7.5. Spain
14.3.7.6. Rest of Europe
14.4. South America
14.4.1. Introduction
14.4.2. Key Region-Specific Dynamics
14.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
14.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
14.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
14.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.4.7.1. Brazil
14.4.7.2. Argentina
14.4.7.3. Rest of South America
14.5. Asia-Pacific
14.5.1. Introduction
14.5.2. Key Region-Specific Dynamics
14.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
14.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
14.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
14.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.5.7.1. China
14.5.7.2. India
14.5.7.3. Japan
14.5.7.4. Australia
14.5.7.5. Rest of Asia-Pacific
14.6. Middle East and Africa
14.6.1. Introduction
14.6.2. Key Region-Specific Dynamics
14.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
14.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
14.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
15. COMPETITIVE LANDSCAPE
15.1. Competitive Scenario
15.2. Market Share Analysis
15.3. Mergers and Acquisitions Analysis
16. COMPANY PROFILES
16.1. Pfizer Inc.*
16.1.1. Company Overview
16.1.2. Product Portfolio and Description
16.1.3. Financial Overview
16.1.4. Key Developments
16.2. ZIM Laboratories Limited
16.3. Aquestive Therapeutics, Inc
16.4. IntelGenx Corp
16.5. Indivior PLC
16.6. C.L.Pharm Co., Ltd
16.7. Seoul Pharmaceuticals
16.8. Shilpa Therapeutics
16.9. Sunovion Pharmaceuticals, Inc
16.10. CURE Pharmaceutical
17. APPENDIX
17.1. About Us and Services
17.2. Contact Us
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Snippet by Product Type
3.2. Snippet by Indication
3.3. Snippet by Route of Administration
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increase in incidence of autoimmune disorders, respiratory problems, and cancer to boost the market growth
4.1.1.2. The increase in medication and pharmacological therapy usage
4.1.2. Restraints
4.1.2.1. Regulatory challenges for transmucosal drug
4.1.3. Opportunity
4.1.3.1. Increasing number of research and developments activities
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
6. COVID-19 ANALYSIS
6.1. Analysis of COVID-19
6.1.1. Before COVID-19 Scenario
6.1.2. Present COVID-19 Scenario
6.1.3. Post COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. RUSSIA-UKRAINE CONFLICT ANALYSIS
8. GLOBAL RECESSION ANALYSIS
9. ARTIFICIAL INTELLIGENCE IMPACT ANALYSIS
10. BY PRODUCT TYPE
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.1.2. Market Attractiveness Index, By Product Type
10.2. Tablets
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Films
10.4. Liquids & Spray
10.5. Others
11. BY INDICATION
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
11.1.2. Market Attractiveness Index, By Indication
11.2. Opioid Dependence *
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Neurological Disorders
11.4. Erectile Dysfunction
11.5. Nausea and Vomiting
11.6. Others
12. BY ROUTE OF ADMINISTRATION
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.1.2. Market Attractiveness Index, By Route of Administration
12.2. Sublingual Mucosa *
12.2.1. Introduction
12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.3. Buccal Mucosa
12.4. Others
13. BY DISTRIBUTION CHANNEL
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13.1.2. Market Attractiveness Index, By Distribution Channel
13.2. Retail Pharmacies*
13.2.1. Introduction
13.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
13.3. Hospital Pharmacies
13.4. Online Pharmacies
14. BY REGION
14.1. Introduction
14.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
14.1.2. Market Attractiveness Index, By Region
14.2. North America
14.2.1. Introduction
14.2.2. Key Region-Specific Dynamics
14.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
14.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
14.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
14.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.2.7.1. The U.S.
14.2.7.2. Canada
14.2.7.3. Mexico
14.3. Europe
14.3.1. Introduction
14.3.2. Key Region-Specific Dynamics
14.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
14.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
14.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
14.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.3.7.1. Germany
14.3.7.2. The U.K.
14.3.7.3. France
14.3.7.4. Italy
14.3.7.5. Spain
14.3.7.6. Rest of Europe
14.4. South America
14.4.1. Introduction
14.4.2. Key Region-Specific Dynamics
14.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
14.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
14.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
14.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.4.7.1. Brazil
14.4.7.2. Argentina
14.4.7.3. Rest of South America
14.5. Asia-Pacific
14.5.1. Introduction
14.5.2. Key Region-Specific Dynamics
14.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
14.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
14.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
14.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.5.7.1. China
14.5.7.2. India
14.5.7.3. Japan
14.5.7.4. Australia
14.5.7.5. Rest of Asia-Pacific
14.6. Middle East and Africa
14.6.1. Introduction
14.6.2. Key Region-Specific Dynamics
14.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
14.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
14.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
15. COMPETITIVE LANDSCAPE
15.1. Competitive Scenario
15.2. Market Share Analysis
15.3. Mergers and Acquisitions Analysis
16. COMPANY PROFILES
16.1. Pfizer Inc.*
16.1.1. Company Overview
16.1.2. Product Portfolio and Description
16.1.3. Financial Overview
16.1.4. Key Developments
16.2. ZIM Laboratories Limited
16.3. Aquestive Therapeutics, Inc
16.4. IntelGenx Corp
16.5. Indivior PLC
16.6. C.L.Pharm Co., Ltd
16.7. Seoul Pharmaceuticals
16.8. Shilpa Therapeutics
16.9. Sunovion Pharmaceuticals, Inc
16.10. CURE Pharmaceutical
17. APPENDIX
17.1. About Us and Services
17.2. Contact Us
LIST OF TABLES
Table 1Global Oral Transmucosal Drugs Market Value, By Product Type, 2022, 2026 & 2030 ($ Million)
Table 2Global Oral Transmucosal Drugs Market Value, By Indication, 2022, 2026 & 2030 ($ Million)
Table 3Global Oral Transmucosal Drugs Market Value, By Route of Administration, 2022, 2026 & 2030 ($ Million)
Table 4Global Oral Transmucosal Drugs Market Value, By Distribution Channel, 2022, 2026 & 2030 ($ Million)
Table 5Global Oral Transmucosal Drugs Market Value, By Region, 2022, 2026 & 2030 ($ Million)
Table 6Global Oral Transmucosal Drugs Market Value, By Product Type, 2022, 2026 & 2030 ($ Million)
Table 7Global Oral Transmucosal Drugs Market Value, By Product Type, 2021-2030 ($ Million)
Table 8Global Oral Transmucosal Drugs Market Value, By Indication, 2022, 2026 & 2030 ($ Million)
Table 9Global Oral Transmucosal Drugs Market Value, By Indication, 2021-2030 ($ Million)
Table 10Global Oral Transmucosal Drugs Market Value, By Route of Administration, 2022, 2026 & 2030 ($ Million)
Table 11Global Oral Transmucosal Drugs Market Value, By Route of Administration, 2021-2030 ($ Million)
Table 12Global Oral Transmucosal Drugs Market Value, By Distribution Channel, 2022, 2026 & 2030 ($ Million)
Table 13Global Oral Transmucosal Drugs Market Value, By Distribution Channel, 2021-2030 ($ Million)
Table 14Global Oral Transmucosal Drugs Market Value, By Region, 2022, 2026 & 2030 ($ Million)
Table 15Global Oral Transmucosal Drugs Market Value, By Region, 2021-2030 ($ Million)
Table 16North America Oral Transmucosal Drugs Market Value, By Product Type, 2021-2030 ($ Million)
Table 17North America Oral Transmucosal Drugs Market Value, By Indication, 2021-2030 ($ Million)
Table 18North America Oral Transmucosal Drugs Market Value, By Route of Administration, 2021-2030 ($ Million)
Table 19North America Oral Transmucosal Drugs Market Value, By Distribution Channel, 2021-2030 ($ Million)
Table 20North America Oral Transmucosal Drugs Market Value, By Country, 2021-2030 ($ Million)
Table 21South America Oral Transmucosal Drugs Market Value, By Product Type, 2021-2030 ($ Million)
Table 22South America Oral Transmucosal Drugs Market Value, By Indication, 2021-2030 ($ Million)
Table 23South America Oral Transmucosal Drugs Market Value, By Route of Administration, 2021-2030 ($ Million)
Table 24South America Oral Transmucosal Drugs Market Value, By Distribution Channel, 2021-2030 ($ Million)
Table 25South America Oral Transmucosal Drugs Market Value, By Country, 2021-2030 ($ Million)
Table 26Europe Oral Transmucosal Drugs Market Value, By Product Type, 2021-2030 ($ Million)
Table 27Europe Oral Transmucosal Drugs Market Value, By Indication, 2021-2030 ($ Million)
Table 28Europe Oral Transmucosal Drugs Market Value, By Route of Administration, 2021-2030 ($ Million)
Table 29Europe Oral Transmucosal Drugs Market Value, By Distribution Channel, 2021-2030 ($ Million)
Table 30Europe Oral Transmucosal Drugs Market Value, By Country, 2021-2030 ($ Million)
Table 31Asia-Pacific Oral Transmucosal Drugs Market Value, By Product Type, 2021-2030 ($ Million)
Table 32Asia-Pacific Oral Transmucosal Drugs Market Value, By Indication, 2021-2030 ($ Million)
Table 33Asia-Pacific Oral Transmucosal Drugs Market Value, By Route of Administration, 2021-2030 ($ Million)
Table 34Asia-Pacific Oral Transmucosal Drugs Market Value, By Distribution Channel, 2021-2030 ($ Million)
Table 35Asia-Pacific Oral Transmucosal Drugs Market Value, By Country, 2021-2030 ($ Million)
Table 36Middle East & Africa Oral Transmucosal Drugs Market Value, By Product Type, 2021-2030 ($ Million)
Table 37Middle East & Africa Oral Transmucosal Drugs Market Value, By Indication, 2021-2030 ($ Million)
Table 38Middle East & Africa Oral Transmucosal Drugs Market Value, By Route of Administration, 2021-2030 ($ Million)
Table 39Middle East & Africa Oral Transmucosal Drugs Market Value, By Distribution Channel, 2021-2030 ($ Million)
Table 40Pfizer Inc.: Overview
Table 41Pfizer Inc.: Product Portfolio
Table 42Pfizer Inc.: Key Developments
Table 43ZIM Laboratories Limited: Overview
Table 44ZIM Laboratories Limited: Product Portfolio
Table 45ZIM Laboratories Limited: Key Developments
Table 46Aquestive Therapeutics, Inc: Overview
Table 47Aquestive Therapeutics, Inc: Product Portfolio
Table 48Aquestive Therapeutics, Inc: Key Developments
Table 49IntelGenx Corp: Overview
Table 50IntelGenx Corp: Product Portfolio
Table 51IntelGenx Corp: Key Developments
Table 52Indivior PLC: Overview
Table 53Indivior PLC: Product Portfolio
Table 54Indivior PLC: Key Developments
Table 55C.L.Pharm Co., Ltd: Overview
Table 56C.L.Pharm Co., Ltd: Product Portfolio
Table 57C.L.Pharm Co., Ltd: Key Developments
Table 58Seoul Pharmaceuticals: Overview
Table 59Seoul Pharmaceuticals: Product Portfolio
Table 60Seoul Pharmaceuticals: Key Developments
Table 61Shilpa Therapeutics: Overview
Table 62Shilpa Therapeutics: Product Portfolio
Table 63Shilpa Therapeutics: Key Developments
Table 64Sunovion Pharmaceuticals, Inc: Overview
Table 65Sunovion Pharmaceuticals, Inc: Product Portfolio
Table 66Sunovion Pharmaceuticals, Inc: Key Developments
Table 67CURE Pharmaceutical: Overview
Table 68CURE Pharmaceutical: Product Portfolio
Table 69CURE Pharmaceutical: Key Developments
Table 1Global Oral Transmucosal Drugs Market Value, By Product Type, 2022, 2026 & 2030 ($ Million)
Table 2Global Oral Transmucosal Drugs Market Value, By Indication, 2022, 2026 & 2030 ($ Million)
Table 3Global Oral Transmucosal Drugs Market Value, By Route of Administration, 2022, 2026 & 2030 ($ Million)
Table 4Global Oral Transmucosal Drugs Market Value, By Distribution Channel, 2022, 2026 & 2030 ($ Million)
Table 5Global Oral Transmucosal Drugs Market Value, By Region, 2022, 2026 & 2030 ($ Million)
Table 6Global Oral Transmucosal Drugs Market Value, By Product Type, 2022, 2026 & 2030 ($ Million)
Table 7Global Oral Transmucosal Drugs Market Value, By Product Type, 2021-2030 ($ Million)
Table 8Global Oral Transmucosal Drugs Market Value, By Indication, 2022, 2026 & 2030 ($ Million)
Table 9Global Oral Transmucosal Drugs Market Value, By Indication, 2021-2030 ($ Million)
Table 10Global Oral Transmucosal Drugs Market Value, By Route of Administration, 2022, 2026 & 2030 ($ Million)
Table 11Global Oral Transmucosal Drugs Market Value, By Route of Administration, 2021-2030 ($ Million)
Table 12Global Oral Transmucosal Drugs Market Value, By Distribution Channel, 2022, 2026 & 2030 ($ Million)
Table 13Global Oral Transmucosal Drugs Market Value, By Distribution Channel, 2021-2030 ($ Million)
Table 14Global Oral Transmucosal Drugs Market Value, By Region, 2022, 2026 & 2030 ($ Million)
Table 15Global Oral Transmucosal Drugs Market Value, By Region, 2021-2030 ($ Million)
Table 16North America Oral Transmucosal Drugs Market Value, By Product Type, 2021-2030 ($ Million)
Table 17North America Oral Transmucosal Drugs Market Value, By Indication, 2021-2030 ($ Million)
Table 18North America Oral Transmucosal Drugs Market Value, By Route of Administration, 2021-2030 ($ Million)
Table 19North America Oral Transmucosal Drugs Market Value, By Distribution Channel, 2021-2030 ($ Million)
Table 20North America Oral Transmucosal Drugs Market Value, By Country, 2021-2030 ($ Million)
Table 21South America Oral Transmucosal Drugs Market Value, By Product Type, 2021-2030 ($ Million)
Table 22South America Oral Transmucosal Drugs Market Value, By Indication, 2021-2030 ($ Million)
Table 23South America Oral Transmucosal Drugs Market Value, By Route of Administration, 2021-2030 ($ Million)
Table 24South America Oral Transmucosal Drugs Market Value, By Distribution Channel, 2021-2030 ($ Million)
Table 25South America Oral Transmucosal Drugs Market Value, By Country, 2021-2030 ($ Million)
Table 26Europe Oral Transmucosal Drugs Market Value, By Product Type, 2021-2030 ($ Million)
Table 27Europe Oral Transmucosal Drugs Market Value, By Indication, 2021-2030 ($ Million)
Table 28Europe Oral Transmucosal Drugs Market Value, By Route of Administration, 2021-2030 ($ Million)
Table 29Europe Oral Transmucosal Drugs Market Value, By Distribution Channel, 2021-2030 ($ Million)
Table 30Europe Oral Transmucosal Drugs Market Value, By Country, 2021-2030 ($ Million)
Table 31Asia-Pacific Oral Transmucosal Drugs Market Value, By Product Type, 2021-2030 ($ Million)
Table 32Asia-Pacific Oral Transmucosal Drugs Market Value, By Indication, 2021-2030 ($ Million)
Table 33Asia-Pacific Oral Transmucosal Drugs Market Value, By Route of Administration, 2021-2030 ($ Million)
Table 34Asia-Pacific Oral Transmucosal Drugs Market Value, By Distribution Channel, 2021-2030 ($ Million)
Table 35Asia-Pacific Oral Transmucosal Drugs Market Value, By Country, 2021-2030 ($ Million)
Table 36Middle East & Africa Oral Transmucosal Drugs Market Value, By Product Type, 2021-2030 ($ Million)
Table 37Middle East & Africa Oral Transmucosal Drugs Market Value, By Indication, 2021-2030 ($ Million)
Table 38Middle East & Africa Oral Transmucosal Drugs Market Value, By Route of Administration, 2021-2030 ($ Million)
Table 39Middle East & Africa Oral Transmucosal Drugs Market Value, By Distribution Channel, 2021-2030 ($ Million)
Table 40Pfizer Inc.: Overview
Table 41Pfizer Inc.: Product Portfolio
Table 42Pfizer Inc.: Key Developments
Table 43ZIM Laboratories Limited: Overview
Table 44ZIM Laboratories Limited: Product Portfolio
Table 45ZIM Laboratories Limited: Key Developments
Table 46Aquestive Therapeutics, Inc: Overview
Table 47Aquestive Therapeutics, Inc: Product Portfolio
Table 48Aquestive Therapeutics, Inc: Key Developments
Table 49IntelGenx Corp: Overview
Table 50IntelGenx Corp: Product Portfolio
Table 51IntelGenx Corp: Key Developments
Table 52Indivior PLC: Overview
Table 53Indivior PLC: Product Portfolio
Table 54Indivior PLC: Key Developments
Table 55C.L.Pharm Co., Ltd: Overview
Table 56C.L.Pharm Co., Ltd: Product Portfolio
Table 57C.L.Pharm Co., Ltd: Key Developments
Table 58Seoul Pharmaceuticals: Overview
Table 59Seoul Pharmaceuticals: Product Portfolio
Table 60Seoul Pharmaceuticals: Key Developments
Table 61Shilpa Therapeutics: Overview
Table 62Shilpa Therapeutics: Product Portfolio
Table 63Shilpa Therapeutics: Key Developments
Table 64Sunovion Pharmaceuticals, Inc: Overview
Table 65Sunovion Pharmaceuticals, Inc: Product Portfolio
Table 66Sunovion Pharmaceuticals, Inc: Key Developments
Table 67CURE Pharmaceutical: Overview
Table 68CURE Pharmaceutical: Product Portfolio
Table 69CURE Pharmaceutical: Key Developments
LIST OF FIGURES
Figure 1Global Oral Transmucosal Drugs Market Share, By Product Type, 2022 & 2030 (%)
Figure 2Global Oral Transmucosal Drugs Market Share, By Indication, 2022 & 2030 (%)
Figure 3Global Oral Transmucosal Drugs Market Share, By Route of Administration, 2022 & 2030 (%)
Figure 4Global Oral Transmucosal Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)
Figure 5Global Oral Transmucosal Drugs Market Share, By Region, 2022 & 2030 (%)
Figure 6Global Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)
Figure 7Global Oral Transmucosal Drugs Market Y-o-Y Growth, By Product Type, 2021-2030 (%)
Figure 8Tablets: Global Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)
Figure 9Films: Global Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)
Figure 10Liquids & Spray: Global Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)
Figure 11Others: Global Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)
Figure 12Global Oral Transmucosal Drugs Market Y-o-Y Growth, By Indication, 2021-2030 (%)
Figure 13Opioid Dependence: Global Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)
Figure 14Neurological Disorders: Global Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)
Figure 15Erectile Dysfunction: Global Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)
Figure 16Nausea and Vomiting: Global Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)
Figure 17Others: Global Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)
Figure 18Global Oral Transmucosal Drugs Market Y-o-Y Growth, By Route of Administration, 2021-2030 (%)
Figure 19Sublingual Mucosa: Global Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)
Figure 20Buccal Mucosa: Global Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)
Figure 21Others: Global Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)
Figure 22Global Oral Transmucosal Drugs Market Y-o-Y Growth, By Distribution Channel, 2021-2030 (%)
Figure 23Retail Pharmacies: Global Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)
Figure 24Hospital Pharmacies: Global Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)
Figure 25Online Pharmacies: Global Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)
Figure 26Global Oral Transmucosal Drugs Market Y-o-Y Growth, By Region, 2021-2030 (%)
Figure 27North America Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)
Figure 28North America Oral Transmucosal Drugs Market Share, By Product Type, 2022 & 2030 (%)
Figure 29North America Oral Transmucosal Drugs Market Share, By Indication, 2022 & 2030 (%)
Figure 30North America Oral Transmucosal Drugs Market Share, By Route of Administration, 2022 & 2030 (%)
Figure 31North America Oral Transmucosal Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)
Figure 32North America Oral Transmucosal Drugs Market Share, By Country, 2022 & 2030 (%)
Figure 33South America Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)
Figure 34South America Oral Transmucosal Drugs Market Share, By Product Type, 2022 & 2030 (%)
Figure 35South America Oral Transmucosal Drugs Market Share, By Indication, 2022 & 2030 (%)
Figure 36South America Oral Transmucosal Drugs Market Share, By Route of Administration, 2022 & 2030 (%)
Figure 37South America Oral Transmucosal Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)
Figure 38South America Oral Transmucosal Drugs Market Share, By Country, 2022 & 2030 (%)
Figure 39Europe Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)
Figure 40Europe Oral Transmucosal Drugs Market Share, By Product Type, 2022 & 2030 (%)
Figure 41Europe Oral Transmucosal Drugs Market Share, By Indication, 2022 & 2030 (%)
Figure 42Europe Oral Transmucosal Drugs Market Share, By Route of Administration, 2022 & 2030 (%)
Figure 43Europe Oral Transmucosal Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)
Figure 44Europe Oral Transmucosal Drugs Market Share, By Country, 2022 & 2030 (%)
Figure 45Asia-Pacific Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)
Figure 46Asia-Pacific Oral Transmucosal Drugs Market Share, By Product Type, 2022 & 2030 (%)
Figure 47Asia-Pacific Oral Transmucosal Drugs Market Share, By Indication, 2022 & 2030 (%)
Figure 48Asia-Pacific Oral Transmucosal Drugs Market Share, By Route of Administration, 2022 & 2030 (%)
Figure 49Asia-Pacific Oral Transmucosal Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)
Figure 50Asia-Pacific Oral Transmucosal Drugs Market Share, By Country, 2022 & 2030 (%)
Figure 51Middle East & Africa Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)
Figure 52Middle East & Africa Oral Transmucosal Drugs Market Share, By Product Type, 2022 & 2030 (%)
Figure 53Middle East & Africa Oral Transmucosal Drugs Market Share, By Indication, 2022 & 2030 (%)
Figure 54Middle East & Africa Oral Transmucosal Drugs Market Share, By Route of Administration, 2022 & 2030 (%)
Figure 55Middle East & Africa Oral Transmucosal Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)
Figure 56Pfizer Inc.: Financials
Figure 57ZIM Laboratories Limited: Financials
Figure 58Aquestive Therapeutics, Inc: Financials
Figure 59IntelGenx Corp: Financials
Figure 60Indivior PLC: Financials
Figure 61C.L.Pharm Co., Ltd: Financials
Figure 62Seoul Pharmaceuticals: Financials
Figure 63Shilpa Therapeutics: Financials
Figure 64Sunovion Pharmaceuticals, Inc: Financials
Figure 65CURE Pharmaceutical: Financials
Figure 1Global Oral Transmucosal Drugs Market Share, By Product Type, 2022 & 2030 (%)
Figure 2Global Oral Transmucosal Drugs Market Share, By Indication, 2022 & 2030 (%)
Figure 3Global Oral Transmucosal Drugs Market Share, By Route of Administration, 2022 & 2030 (%)
Figure 4Global Oral Transmucosal Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)
Figure 5Global Oral Transmucosal Drugs Market Share, By Region, 2022 & 2030 (%)
Figure 6Global Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)
Figure 7Global Oral Transmucosal Drugs Market Y-o-Y Growth, By Product Type, 2021-2030 (%)
Figure 8Tablets: Global Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)
Figure 9Films: Global Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)
Figure 10Liquids & Spray: Global Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)
Figure 11Others: Global Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)
Figure 12Global Oral Transmucosal Drugs Market Y-o-Y Growth, By Indication, 2021-2030 (%)
Figure 13Opioid Dependence: Global Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)
Figure 14Neurological Disorders: Global Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)
Figure 15Erectile Dysfunction: Global Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)
Figure 16Nausea and Vomiting: Global Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)
Figure 17Others: Global Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)
Figure 18Global Oral Transmucosal Drugs Market Y-o-Y Growth, By Route of Administration, 2021-2030 (%)
Figure 19Sublingual Mucosa: Global Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)
Figure 20Buccal Mucosa: Global Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)
Figure 21Others: Global Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)
Figure 22Global Oral Transmucosal Drugs Market Y-o-Y Growth, By Distribution Channel, 2021-2030 (%)
Figure 23Retail Pharmacies: Global Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)
Figure 24Hospital Pharmacies: Global Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)
Figure 25Online Pharmacies: Global Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)
Figure 26Global Oral Transmucosal Drugs Market Y-o-Y Growth, By Region, 2021-2030 (%)
Figure 27North America Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)
Figure 28North America Oral Transmucosal Drugs Market Share, By Product Type, 2022 & 2030 (%)
Figure 29North America Oral Transmucosal Drugs Market Share, By Indication, 2022 & 2030 (%)
Figure 30North America Oral Transmucosal Drugs Market Share, By Route of Administration, 2022 & 2030 (%)
Figure 31North America Oral Transmucosal Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)
Figure 32North America Oral Transmucosal Drugs Market Share, By Country, 2022 & 2030 (%)
Figure 33South America Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)
Figure 34South America Oral Transmucosal Drugs Market Share, By Product Type, 2022 & 2030 (%)
Figure 35South America Oral Transmucosal Drugs Market Share, By Indication, 2022 & 2030 (%)
Figure 36South America Oral Transmucosal Drugs Market Share, By Route of Administration, 2022 & 2030 (%)
Figure 37South America Oral Transmucosal Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)
Figure 38South America Oral Transmucosal Drugs Market Share, By Country, 2022 & 2030 (%)
Figure 39Europe Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)
Figure 40Europe Oral Transmucosal Drugs Market Share, By Product Type, 2022 & 2030 (%)
Figure 41Europe Oral Transmucosal Drugs Market Share, By Indication, 2022 & 2030 (%)
Figure 42Europe Oral Transmucosal Drugs Market Share, By Route of Administration, 2022 & 2030 (%)
Figure 43Europe Oral Transmucosal Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)
Figure 44Europe Oral Transmucosal Drugs Market Share, By Country, 2022 & 2030 (%)
Figure 45Asia-Pacific Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)
Figure 46Asia-Pacific Oral Transmucosal Drugs Market Share, By Product Type, 2022 & 2030 (%)
Figure 47Asia-Pacific Oral Transmucosal Drugs Market Share, By Indication, 2022 & 2030 (%)
Figure 48Asia-Pacific Oral Transmucosal Drugs Market Share, By Route of Administration, 2022 & 2030 (%)
Figure 49Asia-Pacific Oral Transmucosal Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)
Figure 50Asia-Pacific Oral Transmucosal Drugs Market Share, By Country, 2022 & 2030 (%)
Figure 51Middle East & Africa Oral Transmucosal Drugs Market Value, 2021-2030 ($ Million)
Figure 52Middle East & Africa Oral Transmucosal Drugs Market Share, By Product Type, 2022 & 2030 (%)
Figure 53Middle East & Africa Oral Transmucosal Drugs Market Share, By Indication, 2022 & 2030 (%)
Figure 54Middle East & Africa Oral Transmucosal Drugs Market Share, By Route of Administration, 2022 & 2030 (%)
Figure 55Middle East & Africa Oral Transmucosal Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)
Figure 56Pfizer Inc.: Financials
Figure 57ZIM Laboratories Limited: Financials
Figure 58Aquestive Therapeutics, Inc: Financials
Figure 59IntelGenx Corp: Financials
Figure 60Indivior PLC: Financials
Figure 61C.L.Pharm Co., Ltd: Financials
Figure 62Seoul Pharmaceuticals: Financials
Figure 63Shilpa Therapeutics: Financials
Figure 64Sunovion Pharmaceuticals, Inc: Financials
Figure 65CURE Pharmaceutical: Financials
